Evidence map›Paper›PMID 34086984›Full record

ArticleActa psychiatrica Scandinavica2021

Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic.

Simon Lambrichts, Kristof Vansteelandt, Bo Crauwels, Jasmien Obbels, Eva Pilato, Jonas Denduyver, Katrien Ernes, Pieter-Paul Maebe, Charlotte Migchels, Lore Roosen and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Acta psychiatrica Scandinavica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Simon LambrichtsKU Leuven, Department of Neurosciences, Research Group Psychiatry, Neuropsychiatry, Academic Center for ECT and Neuromodulation (AcCENT), University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.ORCID 0000-0002-8951-407X
Kristof VansteelandtKU Leuven, Department of Neurosciences, Research Group Psychiatry, Neuropsychiatry, Academic Center for ECT and Neuromodulation (AcCENT), University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Bo CrauwelsKU Leuven, Department of Neurosciences, Research Group Psychiatry, Neuropsychiatry, Academic Center for ECT and Neuromodulation (AcCENT), University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Jasmien ObbelsKU Leuven, Department of Neurosciences, Research Group Psychiatry, Neuropsychiatry, Academic Center for ECT and Neuromodulation (AcCENT), University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Eva PilatoKU Leuven, Department of Neurosciences, Research Group Psychiatry, Neuropsychiatry, Academic Center for ECT and Neuromodulation (AcCENT), University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Jonas DenduyverKU Leuven, University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Katrien ErnesKU Leuven, University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Pieter-Paul MaebeKU Leuven, University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Charlotte MigchelsKU Leuven, University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Lore RoosenKU Leuven, University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Satya BuggenhoutKU Leuven, University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Filip BouckaertKU Leuven, University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.
Didier SchrijversCollaborative Antwerp Psychiatric Research Institute (CAPRI), UAntwerp, Antwerp, Belgium.
Pascal SienaertKU Leuven, Department of Neurosciences, Research Group Psychiatry, Neuropsychiatry, Academic Center for ECT and Neuromodulation (AcCENT), University Psychiatric Center KU Leuven (UPC KU Leuven, Kortenberg, Belgium.ORCID 0000-0002-0650-415X
KU Leuven · BEUniversity of Antwerp · BE

Funding

Fonds Wetenschappelijk Onderzoek
6 · The paper itself

Abstract

objectiveMaintenance electroconvulsive therapy (M-ECT) is considered an effective relapse prevention strategy in severe mood and psychotic disorders. How long M-ECT should be continued, and what the outcome is after its discontinuation has not been adequately studied. In our tertiary psychiatric hospital, M-ECT treatments were suspended at the start of the COVID-19 pandemic. We aimed to determine the 6-month relapse rate and time to relapse after abrupt discontinuation of M-ECT and to assess the impact of patient and treatment characteristics on the risk of relapse.

methodsEighty-one patients whose M-ECT was discontinued abruptly were followed up prospectively for 6 months, or until relapse (i.e., hospital admission, restart of ECT, change of pharmacotherapy, or suicide (attempt)). We used multivariable Cox proportional hazards models to assess the impact of patient and treatment characteristics on the risk of relapse.

resultsThirty-six patients (44.44%) relapsed within 6 months following abrupt discontinuation of M-ECT. A greater number of previous acute ECT courses, a diagnosis of psychotic disorder (compared with major depressive disorder or bipolar disorder), and a shorter interval between M-ECT treatments at the time of discontinuation were significantly associated with increased risk of relapse.

conclusionAlmost half of the patients relapsed, similar to the relapse rate after a successful acute course of ECT. Patients with a shorter interval between M-ECT treatments at the time of discontinuation seem to be at increased risk, as well as patients with a diagnosis of psychotic disorder, compared to patients with mood disorders.

Indexed as

COVID-19Electroconvulsive TherapyMajor Depressive DisorderHumansPandemicsRecurrenceSARS-CoV-2Treatment OutcomeCOVID-19discontinuationmaintenance electroconvulsive therapyrelapse

Identifiers

PMID34086984
PMCPMC8212096
OpenAlexW3164152886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.